Peramivir
Antiviral
Flu fight uses extreme tactics...lungs, mechanically supplying oxygen to the patient's blood and removing carbon dioxide. The other is an intravenous flu medicine called peramivir (per-AM-uh-veer), which last month received emergency approval for use from the federal... |
-
AP Online | 3 days ago
BioCryst prices stock offering at $9.75 per share
If all 5.75 million shares are sold, BioCryst's share count will rise almost 15 percent. BioCryst's most advanced drug candidate is peramivir, a flu drug intended to be given by IV to patients who are too sick to take an oral dose.
In this article: Birmingham and Alabama
-
BioCryst Pharma to sell up to 5.75M new shares
...book-runner for the offering, and JMP Securities and Oppenheimer & Co. will be co-managers. BioCryst's most advanced drug candidate is peramivir, a flu drug intended to be given by IV to patients who are too sick to take an oral dose.
In this article: Oppenheimer & Co., Morgan Stanley, Birmingham, and Alabama
-
Reuters | November 12, 2009
H1N1 has killed 3,900 Americans: CDC
...with antiviral drugs such as Tamiflu, made by Roche AG, Relenza, made by GlaxoSmithKline or for especially grave hospitalized cases, peramivir, made by BioCryst. Schuchat stressed the pandemic was not worsening but noted that it takes...
In this article: United States, Relenza, Tamiflu, GlaxoSmithKline, and U.S. Centers for Disease Control and Prevention
-
USATODAY.com | November 12, 2009
CDC: Swine flu sickened 22M in U.S.
In this article: United States, Relenza, Tamiflu, GlaxoSmithKline, U.S. Centers for Disease Control and Prevention, and Washington
-
H1N1 has killed 3,900 Americans, CDC says
In this article: United States, Relenza, Tamiflu, NYSE, Nasdaq, GlaxoSmithKline, and U.S. Centers for Disease Control and Prevention
-
The Seattle Times | November 05, 2009
BioCryst receives $22.5 million peramivir order
Originally published Thursday, November 5, 2009 at 5:56 AM BioCryst receives $22.5 million peramivir order BioCryst Pharmaceuticals Inc. said Thursday it will receive $22.5 million as part of a new contract with the Department of Health...
In this article: Department of Health and Human Services
Trends
Loading...
More on Peramivir
Description from Wikipedia:
Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.
BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies. ==Sources==
Explore everything named Peramivir...
